GO:0140865 interleukin-22-mediated signaling pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0140865 describes the molecular signaling cascade triggered when interleukin-22 (IL-22) binds its receptor on target cells, culminating in regulation of downstream cellular processes such as transcription.
• IL-22 signaling promotes aerobic glycolysis in human colon cancer cells by targeting hexokinase-2 (HK2), linking this pathway to tumor progression.
• The pathway is a biological process (GO:0140865) with synonyms IL-22-mediated signaling pathway and interleukin-22-mediated signalling pathway.
• Key molecular players include IL-22, the heterodimeric receptor IL-22R1/IL-10R2, JAK kinases, STAT transcription factors, and downstream effectors like HK2.
• Dysregulated IL-22 signaling is implicated in cancer, inflammatory diseases, and tissue repair, making it a target for therapeutic intervention.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable precise dissection of IL-22 pathway components and their roles in disease.
Description
The interleukin-22-mediated signaling pathway (GO:0140865) is a biological process that begins with the binding of interleukin-22 (IL-22) to its receptor on the surface of a target cell and ends with the regulation of downstream cellular processes, such as transcription. IL-22 is a cytokine that plays critical roles in immune regulation, tissue homeostasis, and inflammation. Understanding this pathway is essential for researchers studying cancer, autoimmunity, and infectious diseases, as it can drive both protective and pathogenic outcomes. Recent studies have demonstrated that IL-22 signaling promotes aerobic glycolysis in human colon cancer cells by targeting hexokinase-2 (HK2), directly linking this pathway to metabolic reprogramming and tumor progression. This article provides a comprehensive overview of the GO:0140865 term, its molecular components, regulatory mechanisms, disease associations, and the CRISPR-based research tools available to investigate it.
interleukin-22-mediated signaling pathway At A Glance
| GO ID | GO:0140865 |
|---|---|
| GO term | interleukin-22-mediated signaling pathway |
| Ontology | biological_process |
| Synonym | IL-22-mediated signaling pathway; interleukin-22-mediated signalling pathway |
| Major function | Transduces IL-22 cytokine signals from the cell surface to the nucleus, regulating gene expression and cellular processes such as glycolysis |
| Key receptor | Heterodimeric receptor complex of IL-22R1 (IL22RA1) and IL-10R2 (IL10RB) |
| Major downstream effectors | JAK kinases, STAT transcription factors (e.g., STAT3), hexokinase-2 (HK2) |
| Associated diseases | Colon cancer, inflammatory bowel disease, psoriasis, tissue repair disorders |
What Is GO:0140865?
GO:0140865, the interleukin-22-mediated signaling pathway, is defined as the series of molecular signals initiated by interleukin-22 binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription. This process encompasses receptor activation, intracellular signal transduction, and transcriptional regulation, ultimately influencing cell behavior, metabolism, and survival.
Why Is interleukin-22-mediated signaling pathway Important in Cell Biology?
The interleukin-22-mediated signaling pathway is critically important because it bridges immune signaling and cellular metabolism, influencing outcomes in cancer, inflammation, and tissue regeneration. In colon cancer, IL-22 signaling promotes aerobic glycolysis via HK2, supporting tumor progression and offering a potential therapeutic target. Understanding this pathway at the molecular level can reveal new biomarkers and intervention strategies for diseases driven by dysregulated IL-22 activity.
• Drives metabolic reprogramming in cancer cells by upregulating hexokinase-2 (HK2).
• Plays a dual role in inflammation: protective in tissue repair but pathogenic in chronic inflammatory diseases.
• Serves as a potential therapeutic target in colon cancer and other malignancies.
• Modulates immune cell function and epithelial barrier integrity.
• Involved in host defense against bacterial and fungal infections.
• Contributes to autoimmune diseases such as psoriasis and inflammatory bowel disease.
• Regulates cell survival, proliferation, and differentiation via STAT signaling.
• Provides a model for studying cytokine-receptor signaling crosstalk.
• Enables CRISPR-based functional genomics to identify novel pathway components.
• Offers opportunities for drug discovery targeting IL-22/IL-22R interaction.
What Happens During interleukin-22-mediated signaling pathway?
IL-22 Binding and Receptor Activation
In simple terms: IL-22 acts like a key that fits into a specific lock on the cell surface, starting a chain reaction inside the cell.
The pathway begins when interleukin-22 (IL-22) binds to its heterodimeric receptor complex composed of IL-22R1 and IL-10R2 on the surface of target cells. This binding induces conformational changes that activate receptor-associated JAK kinases, leading to phosphorylation of the receptor intracellular domains.
JAK-STAT Signal Transduction
In simple terms: Activated JAK enzymes add phosphate tags to STAT proteins, which then travel to the nucleus to switch genes on or off.
Activated JAK kinases phosphorylate STAT proteins, primarily STAT3, which then dimerize and translocate to the nucleus. In the nucleus, STAT dimers bind to specific DNA response elements and regulate transcription of target genes, including those involved in glycolysis and cell survival.
Metabolic Reprogramming via HK2
In simple terms: The signal turns up the activity of a key enzyme that helps cancer cells consume more sugar for rapid growth.
In human colon cancer cells, IL-22 signaling promotes aerobic glycolysis by targeting hexokinase-2 (HK2). This metabolic shift supports tumor progression by providing energy and biosynthetic precursors for proliferating cancer cells.
Regulation of Downstream Cellular Processes
In simple terms: The final outcome is changes in how the cell behaves, such as growing faster or surviving stress.
The pathway culminates in the regulation of various downstream cellular processes, including transcription, cell proliferation, survival, and differentiation. These effects are context-dependent and can vary by cell type and disease state.
Key Genes Involved in GO:0140865 interleukin-22-mediated signaling pathway
The following genes and proteins are central to the interleukin-22-mediated signaling pathway, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IL22 | Ligand that initiates signaling by binding to IL-22R1 | Target for modulating pathway activity in cancer and inflammation |
| IL22RA1 | Subunit of the IL-22 receptor complex; binds IL-22 | Determines cell-type specificity of IL-22 responses |
| IL10RB | Shared receptor subunit required for signal transduction | Essential for JAK activation and downstream signaling |
| JAK1 | Kinase that phosphorylates receptor and STAT proteins | Key mediator of signal transduction; target for inhibitors |
| TYK2 | Kinase associated with IL-10R2; contributes to STAT activation | Modulates signaling strength and specificity |
| STAT3 | Transcription factor that translocates to nucleus and regulates gene expression | Central effector of IL-22-induced transcription |
| STAT1 | Transcription factor activated in some contexts | May mediate alternative or opposing effects |
| HK2 | Hexokinase-2; enzyme upregulated by IL-22 signaling | Promotes aerobic glycolysis and tumor progression in colon cancer |
| SOCS3 | Negative regulator of cytokine signaling | Feedback inhibitor of IL-22 pathway |
| PIAS3 | Protein inhibitor of activated STAT3 | Modulates STAT3 transcriptional activity |
| SHP2 (PTPN11) | Phosphatase that attenuates JAK-STAT signaling | Regulates pathway termination |
| mTOR | Kinase that integrates metabolic signals | May crosstalk with IL-22 signaling to regulate glycolysis |
| MYC | Transcription factor regulating glycolysis and proliferation | Potential downstream target of IL-22 signaling |
| HIF1A | Hypoxia-inducible factor; regulates glycolytic genes | May cooperate with IL-22 to induce HK2 |
| LDHA | Lactate dehydrogenase A; involved in aerobic glycolysis | Downstream metabolic effector |
| SLC2A1 (GLUT1) | Glucose transporter | Facilitates increased glucose uptake in IL-22-stimulated cells |
| BCL2 | Anti-apoptotic protein | May be upregulated by IL-22 signaling to promote survival |
| CCND1 | Cyclin D1; cell cycle regulator | Potential target mediating proliferation |
How Is interleukin-22-mediated signaling pathway Regulated?
The interleukin-22-mediated signaling pathway is tightly regulated at multiple levels. Negative feedback mechanisms include SOCS3, which inhibits JAK kinase activity, and phosphatases such as SHP2 that dephosphorylate signaling intermediates. Additionally, PIAS3 can inhibit STAT3 DNA binding. Crosstalk with other signaling pathways, such as mTOR and HIF1A, can modulate the metabolic outcomes of IL-22 signaling, particularly in cancer cells where aerobic glycolysis is enhanced.
interleukin-22-mediated signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IL22 | Colon cancer progression | IL22 knockout or overexpression in colon cancer cell lines |
| HK2 | Aerobic glycolysis in cancer | HK2 knockout or point mutation to assess metabolic effects |
| STAT3 | Inflammatory bowel disease | STAT3 knockout or knock-in of phospho-mimetic mutants |
| IL22RA1 | Psoriasis | IL22RA1 knockout keratinocytes or skin models |
| SOCS3 | Negative regulation of cytokine signaling | SOCS3 overexpression or knockout to study feedback |
IL-22 Signaling in Colon Cancer
IL-22 signaling promotes aerobic glycolysis in human colon cancer cells by targeting hexokinase-2 (HK2), which supports tumor progression. This metabolic reprogramming provides a growth advantage and is associated with poor clinical outcomes. Targeting IL-22 or HK2 may offer therapeutic benefits in colon cancer.
IL-22 in Inflammatory Diseases
Dysregulated IL-22 signaling contributes to chronic inflammatory conditions such as psoriasis and inflammatory bowel disease. While IL-22 can promote tissue repair, excessive or prolonged signaling may exacerbate inflammation and tissue damage.
IL-22 and Tissue Repair
IL-22 plays a protective role in tissue repair by promoting epithelial cell proliferation and survival. However, in cancer, these same properties can drive tumorigenesis.
From interleukin-22-mediated signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does IL-22 promote tumor growth via HK2? | HK2 knockout in colon cancer cells treated with IL-22 |
| What is the role of STAT3 phosphorylation in IL-22 signaling? | STAT3 point mutation (Y705F) knock-in cells |
| How does IL-22R1 contribute to ligand specificity? | IL22RA1 knockout or knock-in with tagged receptor |
| Can overexpression of IL-22 drive metabolic reprogramming? | IL-22 overexpression in epithelial cell lines |
| What are the downstream targets of IL-22 in inflammation? | STAT3 knockout or overexpression followed by RNA-seq |
| Does SOCS3 feedback regulate IL-22 signaling? | SOCS3 knockout or overexpression models |
How to Study the interleukin-22-mediated signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identify IL-22 target genes |
| ECAR assay | Glycolytic rate | Assess metabolic reprogramming |
| Western blot | Protein phosphorylation and expression | Detect STAT3 activation |
| Co-IP/MS | Protein interactions | Map receptor complex |
| CRISPR knockout screen | Gene essentiality for pathway | Discover novel regulators |
| Luciferase reporter | Transcriptional activity | Measure STAT3-driven promoters |
| Flow cytometry | Cell surface receptor expression | Quantify IL-22R1 levels |
| Metabolomics | Metabolite profiling | Assess glycolysis intermediates |
Transcriptomic Analysis (RNA-seq)
RNA sequencing can identify global transcriptional changes induced by IL-22 signaling, revealing downstream target genes and pathways. This method is useful for comparing wild-type and knockout cells to pinpoint IL-22-regulated genes.
Metabolic Assays
Measurements of glycolysis, such as extracellular acidification rate (ECAR) and lactate production, can quantify the metabolic effects of IL-22 signaling, particularly in cancer cells where HK2 is upregulated.
Protein-Protein Interaction Studies
Co-immunoprecipitation and mass spectrometry can identify components of the IL-22 receptor complex and downstream signaling complexes, helping to map the pathway.
CRISPR Screening
Genome-wide CRISPR knockout screens can uncover novel regulators of IL-22 signaling and its downstream effects, such as genes required for HK2 induction.
How CRISPR Can Be Used to Study GO:0140865 interleukin-22-mediated signaling pathway
Knockout
CRISPR knockout of IL22, IL22RA1, IL10RB, JAK1, TYK2, STAT3, or HK2 can abolish or attenuate IL-22 signaling, enabling researchers to determine the contribution of each component to downstream effects such as glycolysis and proliferation.
Point Mutation
Introducing point mutations (e.g., STAT3 Y705F) can dissect phosphorylation-dependent functions and separate signaling branches. This approach helps identify critical residues required for IL-22-mediated transcription.
Knock-in
Knock-in of tagged versions of IL-22R1 or STAT3 allows for tracking protein localization, interaction partners, and dynamics in live cells. This can reveal spatiotemporal aspects of IL-22 signaling.
Overexpression
Overexpression of IL-22 or constitutively active STAT3 can mimic pathway activation, providing gain-of-function models to study metabolic and oncogenic effects, such as HK2 upregulation.
How EDITGENE Supports interleukin-22-mediated signaling pathway Research
Researchers studying interleukin-22-mediated signaling pathway-related genes often need to determine whether a candidate gene is causally involved in pathway activation, metabolic reprogramming, or disease progression. EDITGENE provides a comprehensive suite of CRISPR-based services to enable precise genetic manipulation and functional interrogation of this pathway.
Contact EDITGENE today to design your custom CRISPR model for interleukin-22-mediated signaling pathway research.
Frequently Asked Questions About interleukin-22-mediated signaling pathway
What is the interleukin-22-mediated signaling pathway?
It is the series of molecular signals initiated by IL-22 binding to its receptor, leading to regulation of downstream cellular processes such as transcription (GO:0140865).
What genes are involved in interleukin-22-mediated signaling pathway?
Key genes include IL22, IL22RA1, IL10RB, JAK1, TYK2, STAT3, and HK2, among others.
How does IL-22 signaling promote cancer?
IL-22 signaling can promote aerobic glycolysis by upregulating hexokinase-2 (HK2), supporting tumor progression in colon cancer.
What is the role of STAT3 in IL-22 signaling?
STAT3 is a transcription factor activated by JAK kinases downstream of IL-22 receptor, and it regulates target gene expression.
What diseases are associated with IL-22 signaling?
Colon cancer, inflammatory bowel disease, psoriasis, and tissue repair disorders have been linked to IL-22 signaling.
How can CRISPR be used to study IL-22 signaling?
CRISPR knockout, point mutation, knock-in, and overexpression models allow precise manipulation of pathway genes to study their functions.
What is the receptor for IL-22?
The IL-22 receptor is a heterodimer of IL-22R1 (IL22RA1) and IL-10R2 (IL10RB).
Does IL-22 signaling affect metabolism?
Yes, IL-22 signaling promotes aerobic glycolysis by targeting hexokinase-2 in human colon cancer cells.
What are the synonyms for GO:0140865?
The synonyms are IL-22-mediated signaling pathway and interleukin-22-mediated signalling pathway.
How is IL-22 signaling regulated?
It is regulated by negative feedback via SOCS3, phosphatases like SHP2, and crosstalk with pathways such as mTOR and HIF1A.
Conclusion
The interleukin-22-mediated signaling pathway (GO:0140865) is a critical biological process linking cytokine signaling to metabolic and transcriptional reprogramming. Its role in promoting aerobic glycolysis via HK2 in colon cancer highlights its importance as a therapeutic target. Continued research using CRISPR-based models will further elucidate its mechanisms and disease relevance.
References
- 1. Liu Y et al.. 2017. Interleukin-22 promotes aerobic glycolysis associated with tumor progression via targeting hexokinase-2 in human colon cancer cells.. Oncotarget 8(15):25372-25383 PMID: 28445985
